Functional changes in Myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs

Journal of Immunology

Volumn 188, Issue 9, 2012, Pages 4226-4234

  Kim, Yun Sun ^a   Kim, Yeon Jeong ^a   Lee, Jung Mi ^a   Kim, Eun Kyung ^a   Park, Young Jun ^a   Choe, Su Kyong ^b   Ko, Hyun Jeong ^c   Kang, Chang Yuil ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CARRIER PROTEINS AND BINDING PROTEINS; FK 506 BINDING PROTEIN 51; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOMERASE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION PROFILING; LYMPHOCYTE FUNCTION; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; ARGINASE; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MYELOID CELLS; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES; TACROLIMUS BINDING PROTEINS; TIME FACTORS;

EID: 84860322833     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103040     Document Type: Article

References (50)

1. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222: 162-179. (Pubitemid 351430364)
2. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
3. Ostrand-Rosenberg, S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59: 1593-1600.
4. Watanabe, S., K. Deguchi, R. Zheng, H. Tamai, L. X. Wang, P. A. Cohen, and S. Shu. 2008. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181: 3291-3300.
5. Hanson, E. M., V. K. Clements, P. Sinha, D. Ilkovitch, and S. Ostrand-Rosenberg. 2009. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183: 937-944.
6. Li, H., Y. Han, Q. Guo, M. Zhang, and X. Cao. 2009. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182: 240-249.
7. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.
8. Yang, L., L. M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, Y. Shyr, L. M. Matrisian, D. P. Carbone, and P. C. Lin. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421. (Pubitemid 39361441)
9. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, and A. J. Montero. 2009. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58: 49-59.
10. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5: 641-654. (Pubitemid 41113195)
11. Pan, P. Y., G. Ma, K. J. Weber, J. Ozao-Choy, G. Wang, B. Yin, C. M. Divino, and S. H. Chen. 2010. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70: 99-108.
12. Talmadge, J. E. 2007. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13: 5243-5248. (Pubitemid 47510346)
13. Ko, H. J., Y. J. Kim, Y. S. Kim, W. S. Chang, S. Y. Ko, S. Y. Chang, S. Sakaguchi, and C. Y. Kang. 2007. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67: 7477-7486. (Pubitemid 47206577)
14. Le, H. K., L. Graham, E. Cha, J. K. Morales, M. H. Manjili, and H. D. Bear. 2009. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9: 900-909.
15. Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
16. Ko, H. J., J. M. Lee, Y. J. Kim, Y. S. Kim, K. A. Lee, and C. Y. Kang. 2009. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J. Immunol. 182: 1818-1828.
17. Lee, J. M., J. H. Seo, Y. J. Kim, Y. S. Kim, H. J. Ko, and C. Y. Kang. 2011. The restoration of myeloid-derived suppressor cells as functional antigen-presenting cells by NKT cell help and all-trans-retinoic acid treatment. Int. J. Cancer. In press.
18. Nefedova, Y., M. Fishman, S. Sherman, X. Wang, A. A. Beg, and D. I. Gabrilovich. 2007. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67: 11021-11028. (Pubitemid 350145932)
19. Kusmartsev, S., F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, and D. Gabrilovich. 2003. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63: 4441-4449. (Pubitemid 36951016)
20. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702. (Pubitemid 44833345)
21. Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, P. Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69: 2514-2522.
22. Chang, S. Y., K. C. Lee, S. Y. Ko, H. J. Ko, and C. Y. Kang. 2004. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int. J. Cancer 111: 86-95. (Pubitemid 38859288)
23. Mukaide, H., Y. Adachi, S. Taketani, M. Iwasaki, N. Koike-Kiriyama, A. Shigematsu, M. Shi, S. Yanai, K. Yoshioka, Y. Kamiyama, and S. Ikehara. 2008. FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma. Cancer Invest. 26: 385-390. (Pubitemid 351601395)
24. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell sub-populations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
25. Peranzoni, E., S. Zilio, I. Marigo, L. Dolcetti, P. Zanovello, S. Mandruzzato, and V. Bronte. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22: 238-244.
26. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
27. Ilkovitch, D., and D. M. Lopez. 2009. Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood 113: 4729-4739.
28. Shi, H., Y. Gu, J. Yang, L. Xu, W. Mi, and W. Yu. 2008. Lipocalin 2 promotes lung metastasis of murine breast cancer cells. J. Exp. Clin. Cancer Res. 27: 83.
29. Yang, J., D. R. Bielenberg, S. J. Rodig, R. Doiron, M. C. Clifton, A. L. Kung, R. K. Strong, D. Zurakowski, and M. A. Moses. 2009. Lipocalin 2 promotes breast cancer progression. Proc. Natl. Acad. Sci. USA 106: 3913-3918.
30. Cheon, E. C., K. Khazaie, M. W. Khan, M. J. Strouch, S. B. Krantz, J. Phillips, N. R. Blatner, L. M. Hix, M. Zhang, K. L. Dennis, et al. 2011. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. Cancer Res. 71: 1627-1636.
31. Nair, S. C., R. A. Rimerman, E. J. Toran, S. Chen, V. Prapapanich, R. N. Butts, and D. F. Smith. 1997. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. Mol. Cell. Biol. 17: 594-603. (Pubitemid 27044358)
32. Staibano, S., M. Mascolo, G. Ilardi, M. Siano, and G. De Rosa. 2011. Immunohistochemical analysis of FKBP51 in human cancers. Curr. Opin. Pharmacol. 11: 338-347.
33. Baughman, G., G. J. Wiederrecht, N. F. Campbell, M. M. Martin, and S. Bourgeois. 1995. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol. Cell. Biol. 15: 4395-4402.
34. Romano, M. F., R. Avellino, A. Petrella, R. Bisogni, S. Romano, and S. Venuta. 2004. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer 40: 2829-2836. (Pubitemid 39574738)
35. Attur, M. G., R. Patel, G. Thakker, P. Vyas, D. Levartovsky, P. Patel, S. Naqvi, R. Raza, K. Patel, D. Abramson, et al. 2000. Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm. Res. 49: 20-26. (Pubitemid 30073182)
36. Tuñón, M. J., S. Sánchez-Campos, B. Gutiérrez, J. M. Culebras, and J. González-Gallego. 2003. Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem. Pharmacol. 66: 439-445. (Pubitemid 36937029)
37. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
38. Komura, E., C. Tonetti, V. Penard-Lacronique, H. Chagraoui, C. Lacout, J. P. Lecouédic, P. Rameau, N. Debili, W. Vainchenker, and S. Giraudier. 2005. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 65: 3281-3289. (Pubitemid 40524612)
39. Bunt, S. K., L. Yang, P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026. (Pubitemid 47621253)
40. Elkabets, M., V. S. Ribeiro, C. A. Dinarello, S. Ostrand-Rosenberg, J. P. Di Santo, R. N. Apte, and C. A. Vosshenrich. 2010. IL-1b regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40: 3347-3357.
41. Vasconcelos, Z. F., B. M. Dos Santos, J. Farache, T. S. Palmeira, R. B. Areal J. M. Cunha, M. A. Barcinski, and A. Bonomo. 2006. G-CSF-treated granulocytes inhibit acute graft-versus-host disease. Blood 107: 2192-2199. (Pubitemid 43289406)
42. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa M. Geilich, G. Winkels, E. Traggiai, A. Casati, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40: 22-35.
43. Nakamura, H., K. Yoshimura, N. G. McElvaney, and R. G. Crystal. 1992. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J. Clin. Invest. 89: 1478-1484.
44. Fadok, V. A., D. L. Bratton, L. Guthrie, and P. M. Henson. 2001. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J. Immunol. 166: 6847-6854. (Pubitemid 32467230)
45. Benarafa, C., G. P. Priebe, and E. Remold-O'Donnell. 2007. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J. Exp. Med. 204: 1901-1909. (Pubitemid 47236325)
46. Hagemann, T., S. K. Biswas, T. Lawrence, A. Sica, and C. E. Lewis. 2009. Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113: 3139-3146.
47. Sica, A., and V. Bronte. 2007. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117: 1155-1166. (Pubitemid 46718400)
48. Wall, M., G. Poortinga, K. M. Hannan, R. B. Pearson, R. D. Hannan, and G. A. McArthur. 2008. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 112: 2305-2317.
49. Guba, M., P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, M. Hornung, C. J. Bruns, C. Zuelke, S. Farkas, M. Anthuber, et al. 2002. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8: 128-135. (Pubitemid 34155123)
50. Chan, S. 2004. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 91: 1420-1424. (Pubitemid 39486341)